Congress programs
Characterization of immune “hot” hormone receptor positive breast cancer
May 2021
Summary
A multi-omic approach to analyze (HR+ve) clinical cohort through; Genomics, Transcriptomics, Proteomics and Radiomics would help to identify groups of patients who can be managed with immune-therapy.
Highlights
- 1
At diagnosis 84% of breast cancer patients have HR+ve tumours indicating positivity for estrogen and/or progesterone receptor (ER, PR), where estrogen and progesterone are key drivers of carcinogenesis.
- 2
Recently the contribution of the immune microenvironment and predicting patient response using either gene expression signatures or through quantitation of tumour-infiltrating lymphocytes (TIL) has been examined. Many of these studies have focused on the triple negative and HER2 list of text fields, add as many as you like Antoine (Version 3: 2020-12-08) positive subgroups as they show extensive immune infiltration and immune scores were found to be highly predictive of survival and response to chemotherapy.
- 3
At present, responses to immune checkpoint inhibitor monotherapy have been marginal in HR+ve breast cancer. However, given the prevalence of HR+ve/HER2-ve breast cancer, identifying even a small subset of immunologically “hot” HR+ve/HER2- tumors could be clinically significant and allow identification of patients likely to benefit from immunotherapy
Comments (0)